- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.02. | Guard Therapeutics International AB Q4 Loss Decreases | 3 | RTTNews | ||
| 05.02. | Guard Therapeutics International AB: Guard Therapeutics Announces Changes to the Company's Management Team | 281 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announces changes to the company's management team, in light of the conclusion of the clinical program for the drug candidate RMC-035 and the ongoing strategic review... ► Artikel lesen | |
| 05.02. | Guard Therapeutics International AB: Guard Therapeutics Provides Status Update Regarding Ongoing Strategic Review | 173 | GlobeNewswire (Europe) | Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") hereby provides a status update regarding the strategic review that the Company announced through a press release on... ► Artikel lesen | |
| 15.01. | Guard Therapeutics International AB: Guard Therapeutics Partners in EU Consortium For Alport Syndrome | 403 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced its participation as a partner in a newly funded European research consortium under the 2025 Joint Transnational Call from the European Rare Diseases Research... ► Artikel lesen | |
| 11.12.25 | Guard Therapeutics International AB (publ) receives observation status | 220 | GlobeNewswire | On December 4, 2025, Guard Therapeutics International AB (publ) (the "Company") issued a press release with information that the Board of Directors of the Company had resolved to commence an exploratory... ► Artikel lesen | |
| GUARD THERAPEUTICS INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 04.12.25 | Guard Therapeutics International AB: Guard Therapeutics Explores Strategic Alternatives | 187 | GlobeNewswire (Europe) | Guard Therapeutics (publ) ("Guard" or the "Company") today announces that the Board of Directors has resolved to commence an exploratory process regarding strategic alternatives, including identifying... ► Artikel lesen | |
| 04.12.25 | Guard Therapeutics International AB: Guard Therapeutics Provides Assessment of Full POINTER Study Results | 166 | GlobeNewswire (Europe) | Guard Therapeutics (public) ("Guard" or "the Company") today provides an assessment of the full results from the Phase 2b POINTER study evaluating RMC-035 in patients undergoing open-heart surgery.... ► Artikel lesen | |
| 13.11.25 | Guard Therapeutics International AB Q3 Loss Narrows | 1 | RTTNews | ||
| 26.10.25 | Guard Therapeutics International AB: Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study | 488 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced top-line results from the company's Phase 2b POINTER study evaluating the investigational drug candidate RMC-035 as a kidney-protective therapy in patients... ► Artikel lesen | |
| 05.10.25 | Guard Therapeutics International AB: Guard Therapeutics Announces New Positive Efficacy Results from Secondary Analyses of the Phase 2a AKITA Study | 217 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced favorable efficacy results from additional analyses of the Phase 2a AKITA study with the investigational drug candidate RMC-035. The previously reported primary... ► Artikel lesen | |
| 11.09.25 | Guard Therapeutics International AB: Guard Therapeutics announces completion of data collection in Phase 2b POINTER study | 747 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced that the last patient in its ongoing Phase 2b clinical trial, POINTER, has successfully completed the final scheduled follow-up visit 90 days after surgery... ► Artikel lesen | |
| 21.08.25 | Guard Therapeutics International AB: Guard Therapeutics publishes interim report January-June 2025 | 235 | GlobeNewswire (Europe) | The quarter marked a key milestone with the completion of patient recruitment for our Phase 2b POINTER study - ahead of schedule. The positive final safety review reinforces confidence in the trial... ► Artikel lesen | |
| 05.06.25 | Guard Therapeutics International AB: Guard Therapeutics announces completion of patient enrollment in Phase 2b POINTER study | 247 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced that the last patient has been successfully enrolled in the company's ongoing Phase 2b clinical trial, POINTER, evaluating the drug candidate RMC-035 as a kidney-protective... ► Artikel lesen | |
| 27.05.25 | Guard Therapeutics International AB: Guard Therapeutics reports positive outcome from second planned safety review in the Phase 2b POINTER study | 290 | GlobeNewswire (Europe) | Guard Therapeutics today announced that an independent Data Safety Monitoring Committee (DSMC) has completed the second and final planned review of safety data from the ongoing Phase 2b clinical trial... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 50,36 | +1,06 % | Novonesis (Novozymes A/S): Resolutions from the Annual General Meeting 2026 | Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2025Approval of distribution of profit... ► Artikel lesen | |
| GENMAB | 226,10 | +0,18 % | Wolfe Research initiates Genmab stock with outperform rating | ||
| ARBUTUS BIOPHARMA | 3,850 | -0,41 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery... ► Artikel lesen | |
| VERICEL | 25,800 | -3,73 % | Vericel-Aktie erreicht Jahrestief bei 29,21 USD | ||
| MUSTGROW BIOLOGICS | 0,345 | 0,00 % | Die Senf-Revolution ist da! Wie der Newcomer MustGrow die Giganten Bayer und K+S herausfordert! | Wir stehen möglicherweise jetzt schon oder in naher Zukunft an einer gefährlichen Weggabelung der Weltgeschichte, an der die bloße Verfügbarkeit von Nahrung zum entscheidenden Machtfaktor wird. Während... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,430 | +0,83 % | Moleculin Biotech, Inc.: Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout | First Interim Unblinding of Pivotal AML Trial Now Imminent - Potentially the Most Important Data Moment in Company HistoryEarly Blinded Results Show 40% Remission Rate Across Difficult-to-Treat Patient... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 27,700 | +3,05 % | Sensei Harbor Corp. - S-1, General form for registration of securities | ||
| BIOXCEL THERAPEUTICS | 1,180 | -0,34 % | BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI Approval in Outpatient Setting | sNDA submitted seeking approval of IGALMI in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia sNDA submission timeline supports... ► Artikel lesen | |
| REGENXBIO | 7,150 | -0,69 % | REGENXBIO Inc.: Regenxbio Reports New Positive Interim Data From Phase I/ii Affinity Duchenne Trial Of Rgx-202 | Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne
Pivotal dose participants exceeded external controls across... ► Artikel lesen | |
| AKEBIA | 1,178 | -1,17 % | Akebia Therapeutics, Inc.: Akebia Announces Establishment of Rare Kidney Disease Pipeline | Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 8,150 | 0,00 % | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 5,400 | +1,89 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | ~ Delivered Record Annual Revenue with Full-Year Net PEDMARK- Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 12,200 | +1,33 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results | Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 4,940 | -0,80 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook | Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential... ► Artikel lesen | |
| NANOBIOTIX | 26,200 | -2,96 % | Nanobiotix S.A.: NANOBIOTIX Statement Regarding Recent Media Speculation | PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches... ► Artikel lesen |
Das Unternehmen GUARD THERAPEUTICS INTERNATIONAL AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -53,14 % bei einem Aktienkurs von 0,019 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GUARD THERAPEUTICS INTERNATIONAL AB finden Sie auf Wallstreet Online.